Home › Compare › NOVN vs QYLD

NOVN vs QYLD: Dividend Comparison 2026

NOVN yields 2125.40% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NOVN wins by $17531898098.61M in total portfolio value
10 years
NOVN
NOVN
● Live price
2125.40%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17531898098.63M
Annual income
$16,046,703,901,914,954.00
Full NOVN calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — NOVN vs QYLD

📍 NOVN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNOVNQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NOVN + QYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NOVN pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NOVN
Annual income on $10K today (after 15% tax)
$180,658.87/yr
After 10yr DRIP, annual income (after tax)
$13,639,698,316,627,710.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, NOVN beats the other by $13,639,698,316,622,900.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NOVN + QYLD for your $10,000?

NOVN: 50%QYLD: 50%
100% QYLD50/50100% NOVN
Portfolio after 10yr
$8765949049.33M
Annual income
$8,023,351,950,960,307.00/yr
Blended yield
91.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NOVN right now

NOVN
Analyst Ratings
2
Buy
2
Hold
Consensus: Buy
Altman Z
-6.8
Piotroski
4/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NOVN buys
0
QYLD buys
0
No recent congressional trades found for NOVN or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNOVNQYLD
Forward yield2125.40% ✓11.92%
Annual dividend / share$2.00$2.04 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$17531898098.63M ✓$25.4K
Annual income after 10y$16,046,703,901,914,954.00 ✓$5,659.31
Total dividends collected$17426965851.86M ✓$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: NOVN vs QYLD ($10,000, DRIP)

YearNOVN PortfolioNOVN Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$223,240$212,539.85$10,352$1,192.36+$212.9K → NOVN
2$4,673,200$4,434,333.16$10,830$1,347.57+$4.66M → NOVN
3$91,753,856$86,753,532.14$11,460$1,539.07+$91.74M → NOVN
4$1,690,067,758$1,591,891,132.54$12,275$1,777.84+$1690.06M → NOVN
5$29,212,083,466$27,403,710,964.97$13,323$2,078.95+$29212.07M → NOVN
6$473,930,931,126$442,674,001,816.98$14,667$2,463.34+$473930.92M → NOVN
7$7,219,118,648,525$6,712,012,552,220.43$16,396$2,960.57+$7219118.63M → NOVN
8$103,276,088,728,702$95,551,631,774,779.60$18,631$3,612.97+$103276088.71M → NOVN
9$1,388,031,959,551,211$1,277,526,544,611,500.20$21,548$4,482.15+$1388031959.53M → NOVN
10$17,531,898,098,634,750$16,046,703,901,914,954.00$25,398$5,659.31+$17531898098.61M → NOVN

NOVN vs QYLD: Complete Analysis 2026

NOVN — Stock

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Full NOVN Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this NOVN vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NOVN vs SCHDNOVN vs JEPINOVN vs ONOVN vs KONOVN vs MAINNOVN vs XYLDNOVN vs JEPQNOVN vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.